Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Pharmacology of Ramelteon, a Selective MT1/MT2Receptor Agonist: A Novel Therapeutic Drug for Sleep Disorders

Open access
Miyamoto, Masaomi·2009·CNS Neuroscience & Therapeutics

Abstract

An estimated one‐third of the general population is affected by insomnia, and this number is increasing due to more stressful working conditions and the progressive aging of society. However, current treatment of insomnia with hypnotics, gamma‐aminobutyric acid A (GABA A) receptor modulators, induces various side effects, including cognitive impairment, motor disturbance, dependence, tolerance, hangover, and rebound insomnia. Ramelteon (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin MT 1/MT 2 receptor agonist. Unlike the sedative hypnotics that target GABA A receptor complexes, ramelteon is a chronohypnotic that acts on the melatonin MT 1 and MT 2 receptors, which are primarily located in the suprachiasmatic nucleus, the body's “master clock.” As such, ramelteon possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades. Ramelteon has demonstrated sleep‐promoting effects in clinical trials, and coupled with its favorable safety profile and lack of abuse potential or dependence, this chronohypnotic provides an important treatment option for insomnia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1755-5949.2008.00066.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 169

Metadata

Authors
Miyamoto, M.
Venue
CNS Neuroscience & Therapeutics
Publisher
Wiley
Published
2009-02-13
Volume
15
Issue
1
Pages
32-51
ISSN
  • 1755-5930 (ISSN-L)
  • 1755-5949
OpenAlex
W2041347130
Cited by
169
References
7
FWCI
3.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacology of Ramelteon, a Selective MT1/MT2Receptor Agonist: A Novel Therapeutic Drug for Sleep Disorders. https://app.cochat.ai/papers/10.1111/j.1755-5949.2008.00066.x
The paper
Miyamoto, M. (2009). Pharmacology of Ramelteon, a Selective MT1/MT2Receptor Agonist: A Novel Therapeutic Drug for Sleep Disorders. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1755-5949.2008.00066.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.